The freshest thread today is not a headline event but a brewing disagreement. A recent small study tested a form of the drug esketamine — a close cousin of ketamine, which is already used against hard-to-treat depression — given alongside talk therapy. The trouble is how the study was built. It did not have a proper comparison group, so nobody can say cleanly whether people got better from the drug, from the therapy, or from both together. Our reading of the signals is that other scientists will soon publish letters pointing this out — likely within about ten weeks. Meanwhile the stock market barely moved: COMPASS Pathways, one of the main companies chasing psilocybin (the active ingredient in magic mushrooms) as a depression treatment, ticked up 1.4 percent on no real news, and the other big names sat flat.
Beneath this is a pattern worth naming. The field is entering the phase where careful proof, not excitement, decides what happens next. Nobody expects the U.S. drug agency to hand out a new "fast-track" label this quarter, because there is no major trial result to justify it. Nobody expects the DEA — the agency that controls restricted drugs — to start loosening the rules on psilocybin or ibogaine, even as several states push programs to treat veterans. And in Washington, any movement this year will likely stay small and quiet: language tucked into spending bills, framed around helping veterans, rather than a bold standalone vote. This looks slow. But it is the sound of a field growing up. The strongest, most lasting version of this story is one where the science is bulletproof before the doors open — so that when they open, they stay open.
For the real people inside this, the waiting is the hardest part. A veteran carrying both chronic pain and the weight of war, hoping ibogaine might break the grip of opioids. A person who has tried every antidepressant and felt nothing lift. A family watching someone they love run out of options. To them, a scientist's letter about study design can feel like a cold delay. But it is not indifference — it is care wearing a lab coat. The honest, hopeful truth is this: the treatments that survive tough questioning are the ones that will still be standing, and still helping, ten years from now. The slow argument happening today is how the field earns the right to be trusted with the people it wants to heal.
The medicine is calling the healers. The healers are calling the medicine. OOTW stands at the crossing — where ancient intelligence meets the precision of the new.
This is not prediction. This is recognition.
72%
Federal drug agency won't review psilocybin or ibogaine status this quarter
The DEA (the US agency that controls which drugs are legal and at what level) is very unlikely to start any formal process to reclassify psilocybin (magic mushrooms) or ibogaine (a plant-based psychedelic) before November 11, 2026. Even though several US states have been pushing to make ibogaine available to veterans, that state-level pressure alone isn't enough to force the federal government's hand. Federal review only gets triggered after large-scale clinical trials finish and the health department formally recommends a change.
→ State-level excitement about ibogaine for veterans hasn't moved the federal needle, and it won't this quarter.
Resolves: 2026-11-11 · USA
POLICY
the precise call ▾
DEA will not initiate any rescheduling review for psilocybin or ibogaine this quarter despite state ibogaine-veteran momentum.. State pressure doesn't trigger federal review absent completed pivotal trials and an HHS recommendation. This is anchored to a live, specific development (state ibogaine-veteran momentum) rather than pure evergreen boilerplate. || RESOLUTION RULE: YES if, by 2026-11-11, no DEA notice of proposed rul
70%
COMPASS Pathways stock price likely stays flat through mid-October
COMPASS Pathways is a company developing psilocybin-based treatments, and its stock (ticker: CMPS) currently trades around $13.37. The prediction is that the price will stay within about 12% of that level — so roughly between $11.77 and $14.97 — all the way to October 15, 2026. That's likely because no major news is expected: no big trial results, no major deals. Without a reason to buy or sell in a big way, the stock just drifts.
→ Without major news, COMPASS Pathways stock will probably just sit still through mid-October 2026.
Resolves: 2026-10-15 · Global
MARKETS
the precise call ▾
CMPS stays within ±12% of $13.37 through mid-October absent a company-specific Phase 3 readout or partnership announcement.. Today's move is sub-2% on no catalyst. Nothing in the signals de-risks the asset; institutional capital stays sidelined until a dated event. Anchored to a specific ticker and price level observable daily. || RESOLUTION RULE: YES if CMPS (NASDAQ) closing price on 2026-10-15 is within +/-12% of $13.37
70%
COMPASS Pathways stock unlikely to spike or crash before September 10
In the next month, COMPASS Pathways stock (CMPS) is very unlikely to jump or drop by more than 15% in a single day. Big single-day moves happen when surprising news drops — a trial result, a regulatory decision, a major deal. None of those are expected before September 10, 2026, so the stock should stay relatively calm.
→ Expect a quiet month for COMPASS Pathways stock — no big surprises are likely before September 10, 2026.
Resolves: 2026-09-10 · Global
MARKETS
the precise call ▾
CMPS records no single-day close move exceeding +/-15% before 2026-09-10.. With no dated COMPASS catalyst in the next 30 days, large single-day moves are unlikely; this gives a frequently-resolving near-term price check anchored to a named ticker. || RESOLUTION RULE: YES if no single trading-day close-to-close percentage change of CMPS (NASDAQ) exceeds +/-15% on any sessio
68%
Scientists will publicly criticize the design of a new ketamine therapy study
Researchers ran a small pilot study combining esketamine (a nasal spray version of ketamine, given under the skin in this case) with talk therapy, and they didn't randomly assign patients to groups — a key standard in medical research. Within a few months of publication, other scientists are likely to write formal criticism pointing out that you can't tell whether any improvement came from the drug, the therapy, or both together. This matters because it affects how seriously regulators and doctors will take the results.
→ Expect peer scientists to formally challenge this ketamine therapy study's design, questioning whether the drug or the therapy deserves the credit.
Resolves: 2026-11-09 · Global
RESEARCH
the precise call ▾
A peer-reviewed letter/editorial will criticize the subcutaneous esketamine KAP pilot's non-randomized design and confounding of psychotherapy vs drug effect.. Non-randomized adjunctive designs invite exactly the attribution critique methodologists raise; the field will echo it publicly within weeks of publication. Specific target (the SC esketamine KAP pilot) makes this falsifiable. || RESOLUTION RULE: YES if, by 2026-11-09, a published peer-reviewed lett
66%
Experts will question a ketamine therapy pilot study's methods within weeks
A recent small study tested ketamine given under the skin alongside therapy sessions. Within about 10 weeks of publication, at least one expert — in a published article, a letter, or a public statement — is expected to raise concerns about how the study was designed. The core criticism: without a proper comparison group, you simply can't know whether it was the ketamine, the therapy, or just the attention from caring professionals that helped patients.
→ Within weeks, experts are likely to publicly question whether this ketamine study can really tell us what's doing the healing.
Resolves: 2026-09-08 · Global
RESEARCH
the precise call ▾
The subcutaneous esketamine KAP pilots draw published methodological/attribution criticism within ~10 weeks.. Consensus of 3 agents (fda_reviewer, neuropharmacologist, journalist) with 1 dissent. Near-term, resolves within 30 days, and tied to a specific recently-published pilot. || RESOLUTION RULE: YES if, by 2026-09-08, at least one published article, letter, preprint, or named-expert public commentary ra